Loading...
BVMF
HYPE3
Market cap2.62bUSD
Apr 29, Last price  
23.32BRL
1D
1.04%
1Q
28.84%
Jan 2017
-10.75%
IPO
190.77%
Name

Hypera SA

Chart & Performance

D1W1MN
P/E
10.99
P/S
1.98
EPS
2.12
Div Yield, %
3.34%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
17.70%
Revenues
7.44b
-5.97%
346,700,000380,267,0001,061,500,0001,332,994,0002,025,272,0003,159,728,0003,324,630,0003,873,683,0004,258,740,0004,680,348,0002,956,649,0003,288,747,0003,638,458,0003,724,309,0003,294,749,0004,088,871,0005,937,373,0007,546,355,0007,914,658,0007,442,466,000
Net income
1.34b
-18.63%
31,000,000-2,932,00042,100,000-207,876,000313,373,000261,901,000-54,651,000203,913,000256,722,000402,695,000559,872,0001,174,574,000964,942,0001,129,601,0001,164,040,0001,295,116,0001,330,208,0001,696,697,0001,647,960,0001,340,990,000
CFO
2.54b
+5.99%
85,262,000193,504,00067,236,000580,234,000713,805,000665,785,000664,001,000323,692,000881,756,000932,612,0001,066,494,000823,882,0001,183,054,0001,399,131,0002,038,793,0002,395,993,0002,539,599,000
Dividend
Sep 24, 20240.19534 BRL/sh
Earnings
Jul 23, 2025

Profile

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
IPO date
Apr 16, 2008
Employees
9,000
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,442,466
-5.97%
7,914,658
4.88%
7,546,355
27.10%
Cost of revenue
5,332,830
4,864,608
4,797,214
Unusual Expense (Income)
NOPBT
2,109,636
3,050,050
2,749,141
NOPBT Margin
28.35%
38.54%
36.43%
Operating Taxes
(353,762)
(141,638)
(95,348)
Tax Rate
NOPAT
2,463,398
3,191,688
2,844,489
Net income
1,340,990
-18.63%
1,647,960
-2.87%
1,696,697
27.55%
Dividends
(787,286)
(759,885)
(806,208)
Dividend yield
6.84%
3.36%
2.90%
Proceeds from repurchase of equity
(42,561)
(48,968)
(2,694)
BB yield
0.37%
0.22%
0.01%
Debt
Debt current
1,409,003
2,140,996
2,298,757
Long-term debt
7,988,364
8,188,010
7,590,623
Deferred revenue
Other long-term liabilities
391,988
376,409
405,280
Net debt
7,658,040
7,627,474
6,895,190
Cash flow
Cash from operating activities
2,539,599
2,395,993
2,038,793
CAPEX
(429,392)
(814,778)
(1,509,456)
Cash from investing activities
(592,438)
(791,188)
(1,742,337)
Cash from financing activities
(2,788,727)
(1,886,385)
278,955
FCF
2,679,938
2,115,441
1,414,412
Balance
Cash
1,739,327
2,580,893
2,862,473
Long term investments
120,639
131,717
Excess cash
1,367,204
2,305,799
2,616,872
Stockholders' equity
9,711,424
11,538,150
10,742,575
Invested Capital
20,523,970
19,699,712
18,212,324
ROIC
12.25%
16.84%
16.85%
ROCE
9.58%
13.86%
13.20%
EV
Common stock shares outstanding
636,247
637,793
639,103
Price
18.09
-48.96%
35.44
-18.40%
43.43
53.63%
Market cap
11,509,700
-49.08%
22,603,384
-18.56%
27,756,243
53.52%
EV
19,173,278
30,244,607
34,661,114
EBITDA
2,390,691
3,288,362
2,918,242
EV/EBITDA
8.02
9.20
11.88
Interest
971,047
1,349,523
986,082
Interest/NOPBT
46.03%
44.25%
35.87%